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Abstract 
Relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) is associated with a relatively poor outcome 
once patients become resistant to traditional chemotherapy and new approaches are needed. Brentuximab 
vedotin (BV) is a novel anti-CD30 monoclonal antibody conjugated to the antimicrotubule cytotoxic 
monomethyl auristatin-E (MMAE). BV has been licenced and routinely used in patients who relapse after 
autologous stem cell transplant (SCT) since 2012. BV is also licensed in patients who have received two prior 
lines of therapy and who are not suitable for ASCT. There are very limited data on the efficacy of both the 
efficacy of BV in this setting; in particular the ability of the agent to enable suitability for autologous or 
allogenic SCT by inducing or deepening remissions. We performed a UK-wide retrospective multi-centre study of 
99 SCT-naïve R/R cHL patients who received BV to assess the success of incorporating this agent pre-SCT. All 
had previously received two or more prior chemotherapy lines given with curative intent. Patients had all 
received prior salvage with the initial aim to proceed to potential curative SCT but were not deemed suitable 
due to failure of the treatment to induce deep and durable remissions. The median age of the cohort treated 
was 32 years (range 13-70 years) with an equal gender distribution. The majority had nodular sclerosis subtype 
and presented with good performance status and advanced stage disease.  From the point of initial BV 
treatment, the median progression-free survival (PFS) was 5.65 months (95% confidence interval (CI) 4.41 - 
12.20 months) and the median overall survival (OS) was 37.15 months (95% CI 18.28 months - not reached 
(NR)). The overall response rate to BV was 56% (complete metabolic response/complete response/complete 
response unconfirmed (CMR/CR/CRu) 29% plus partial metabolic response/partial response (PMR/PR) 27%). 
The median duration of response on those entering a CR was superior to that of a PR, consistent with previous 
reports. Multivariate Cox regression revealed that patients with improved performance status and 
haemoglobin at first relapse had an improved PFS from the start of BV. We demonstrate that BV has activity 
and is a non-toxic option in a cohort of high risk, predominantly refractory cHL, although the PFS of 5.65 
months demonstrates that further work is required to improve outcomes in this high risk patient population.  
Background and introduction 
Classical Hodgkin lymphoma (cHL) is typically a highly chemosensitive and curable B-cell malignancy, with 
approximately 2000 new annual cases per year in the UK (Smith et al., 2015). Newly diagnosed cHL are often 
managed according to whether the patient has early favourable, early unfavourable and late stage disease 
(Follows et al., 2014). Early stage disease is typically treated with combined modality therapy, most often with 
ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and radiotherapy (RT). There is currently a lack of 
international consensus regarding the optimal first line treatment for advanced stage cHL. ABVD is favoured in 
the UK, some parts of continental Europe, Australia and the USA, whereas in Germany and other parts of 
Europe, BEACOPPESCALATED (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, prednisolone, 
procarbazine) is standard. Bleomycin is now frequently discontinued in patients who are interim PET negative 
after two cycles of ABVD in advanced stage disease (Johnson et al., 2016). Patients that are refractory to or 
who relapse after front line therapy are uncommon but represent a significant challenge and those patients 
that subsequently relapse or are refractory to first line salvage represent a clear area of need where the 
optimum therapeutic approach remains unknown.  
Brentuximab Vedotin (BV) is a novel anti-CD30 monoclonal antibody conjugated to the antimicrotubule 
cytotoxic monomethyl auristatin-E (MMAE). BV is licenced in patients who relapse after autologous stem cell 
transplant. BV has been used routinely in this setting as a standard of care since 2012. BV is also licensed in 
patients who have received two prior lines of therapy for whom autologous stem cell transplantation ASCT or 
multi-agent chemotherapy is deemed to be not a treatment option. Data generated from the Memorial Sloan 
Kettering group have demonstrated that patients who do not achieve a negative functional imaging scan have 
a low event free survival following subsequent ASCT (Moskowitz, Blood 2010). For this reason, many clinicians 
would regard a patient as not suitable for autologous stem cell transplantation if they have failed to reach a 
complete metabolic remission after salvage therapy. Further salvage treatment is then typically given as a 
means of inducing or deepening responses thus enabling SCT (autologous or, some cases, allogeneic) to go 
ahead in some patients. Within the UK over recent years, patients deemed at high risk of ASCT-failure 
(typically positive PET scan after standard salvage chemotherapy) have often undergone treatment following a 
response-adjusted transplantation algorithm. T cell deplete (alemtuzumab conditioning) allogenic stem cell 
transplantation as a consolidation strategy has been used in those deemed at high risk of ASCT-failure 
following the publication of outcomes following this approach (Thomson et al, 2013). The 3-year PFS of 68% 
and ‘current’ PFS post-donor lymphocyte infusion of 80% of a large retrospective series was encouraging and 
led to the PAIRED trial which is yet to report. Given this impressive long term disease control with relatively 
minimal toxicity this approach has been adopted by several centres and as such, the data presented includes 
the relevant patients in our BV cohort. 
 
There is very limited data on the efficacy of BV prior to planned stem cell transplantation in terms of survival 
rates and ability to enable stem cell transplant to occur. Table 1 highlights the limited experience from small 
case series of up to 30 SCT-naïve patients that have been published. Overall response rates (ORR) vary from 
30% to 71% in patients relapsed or refractory to first line salvage therapy (Forero-Torres et al., 2012; Gibb et 
al., 2013; Onishi et al., 2015; Sasse et al., 2013; Zinzani et al., 2015). Overall response to BV when assessed at 
first relapse, before administration of conventional salvage chemotherapy, was 68% (CR 35%; PR 33%) in a 
phase II trial of 37 patients (Chen et al., 2015).  
Based on this relative paucity of data we therefore sought to assess the activity of BV monotherapy in patients 
fit, but not suitable, for stem cell transplantation, the ability of BV to enable SCT to occur, and the outcome 
and toxicity post-SCT (autologous and allogenic) in a large retrospective UK wide analysis (n = 99).  
Table 1: Summary of Brentuximab Vedotin in the transplant-naïve setting 
Patient 
number 
Criteria Median 
cycles 
of BV 
Response data Transplantation data Reference 
30 PET-positive disease after conventional 
chemotherapy salvage treatments  
4 Normalization of PET (Deauville ≤2) 
in 30% (9/30). 
9 proceeded to ASCT Zinzani et al, 2015 
15 FDG PET positive disease after 
platinum-based salvage  
4 Normalization of FDG PET 
(Deauville ≤2) in 53% (8/15).  
Only observed in patients achieving 
PR or SD after platinum-salvage  
All (n =15) proceeded to 
ASCT, regardless of FDG 
PET status 
Onishi  et al, 2015 
14 No prior autologous SCT due to 
refractory disease (n = 9), co-morbidity 
(n = 4) and unknown reasons (n = 1). 
 ORR 71% (10/14) with 5 PR and 5 
CR  
Consolidating ASCT (n = 
4) or allogeneic SCT (n = 
1)  
Sasse et al, 2013 
20 10 transplant-naïve patients from study 
SG035–0001  
10 transplant-naïve patients from study 
SG035–0002. 
Median prior systemic chemotherapy 
regimens was 3 (range, 1–7). 
3 ORR 30% (6/20) including 2 CR and 
4 PR 
3 of 4 ‘eligible’ patients 
received an ASCT 
Forero-Torres et 
al, 2012 
12 No prior autologous SCT due to 
relapsed, refractory disease 
5.5 ORR was 58% (2 CR, 5 PR) 1 proceeded to allogenic 
SCT 
Gibb et al, 2013 
37 Second-line therapy at first relapse 4 ORR was 68% (25/37) (13 CR, 12 
PR). 
32 proceed to ASCT (18 
directly post-BV; 14 
required salvage 
chemotherapy post-BV, 
pre-ASCT) 
Chen et al, 2015 
 
Material and Methods 
Patient Characteristics 
The purpose of this study was to investigate the efficacy of BV monotherapy in a retrospective, multicentre 
population of patients with relapsed, refractory cHL from across the UK prior to planned SCT. The majority of 
the data was collected from 9 major UK centres, all of whom had treated at least three patients. Patients 
received BV monotherapy from May 2011 to July 2016 when the data was censored. Paper and electronic 
clinical notes were reviewed in all cases. Data was collected typically by the physician who had overseen that 
patient’s care whilst on BV monotherapy. Standard clinical baseline characteristics (age, gender, lactate 
dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al., 1982), 
extranodal disease, B symptoms, Ann Arbor stage, disease bulk, histological subtype) were collected. Known 
risk factors for poor progression free survival (PFS) at first relapse were also collected (haemoglobin, 
extranodal disease, B symptoms, Ann Arbor stage). In addition, details on first, second and third line therapy 
were collected including: a) regimen b) best ORR by PET-CT or CT alone c) length of first remission if obtained 
d) number of lines of prior therapy. Radiotherapy was typically included within a combined treatment modality 
approach and hence was not included as a separate line of prior treatment.  
Adverse event (AE) data were collected including allergic reaction, cytopenias, neutropenic fever (NF), non-
neutropenic fever (NNF), and peripheral neuropathy. Grading of AEs was collected wherever possible. Patient 
follow up was censored at the most recent hospital visit or death. The data were locked and analysed in 
September 2016. 
 
Treatment and Statistical analysis 
Patients received BV monotherapy at 1.8 mg / kg once every three weeks until progression, toxicity or death 
from other causes. PFS was calculated from the initiation of BV to the time of relapse, disease progression, 
death, or censored at the last follow-up. OS was calculated from the initiation of BV monotherapy to date of 
death and was also censored at the last follow-up. Cox regression was used to determine univariate predictors 
of PFS. Independent predictors were identified using multivariate Cox regression. All univariate predictors with 
p < 0.2 were eligible for inclusion in the initial multivariate model, followed by backward selection with the 
Akaike information criterion, AIC (Burnham & Anderson, 2002). Fractional polynomials were used to allow for 
non-linear effects of continuous variables (Royston & Altman, 1994).  All analyses were performed in Stata 13 
(StataCorp, College Station, TX). 
 
Results 
Table II: Baseline Characteristics 
Characteristics BV SCT-naive patients (n = 99) 
At Diagnosis  
Median age (years) at diagnosis 32 years (range 13-70 years) 
Gender 
Male 
Female 
 
45 (45%) 
54 (55%) 
ECOG at diagnosis (n = 86)  
0 
1 
2 
3 
4 
45 (52%) 
36 (42%) 
3 (3%) 
0 (0%) 
2 (2%) 
Histological subtype at diagnosis (n =89) 
Nodular Sclerosis 
Mixed Cellularity 
Lymphocyte Deplete 
Lymphocyte Rich 
 
75 (84%) 
12 (13%) 
1 (1%) 
1 (1%) 
Ann Arbor staging at diagnosis (n = 98) 
1-2 
3-4 
 
28 (29%) 
70 (71%) 
Bulk at diagnosis > 10 cm (n = 95) 
N 
Y 
 
75 (79%) 
20 (21%) 
Length of first remission: earliest remission to relapse 
(n = 66) 
Median 6.00 months (range 0.66 – 74.07 months) 
 
Risk factors at relapse 
Haemoglobin (n = 80) 
≥ 12 
< 12 
Extranodal disease at first relapse (n = 94) 
Y 
N 
B symptoms at first relapse (n = 88) 
Y 
N 
Ann Arbor stage at first relapse (n = 94) 
1-2 
3-4 
 
Median 12.2 g/dL (range 6.6 – 15.3 g/dL) 
41 (51%) 
39 (49%) 
 
44 (47%) 
50 (53%) 
 
33 (38%) 
55 (62%) 
 
27 (29%) 
67 (71%) 
Median time from last treatment to BV (n = 94) 2.53 months (range 0.72 – 34.8 months) 
Median time from initial diagnosis to BV (n = 99) 14.53 months (range 4.01 – 190.95 months) 
Prior lines of therapy pre BV (n = 99) 
2 
3 
4 
Median number of prior chemotherapy lines 
 
70 
24 
5 
2 (range 2-4) 
Response to BV (n = 96) 
ORR 
CMR / CR / CRu 
PMR / PR 
SD 
PD 
 
54 (56%) 
24 (25%) / 3 (3%) / 1 (1%) 
2 (2%) / 24 (24%)  
8 (8%) 
34 (35%) 
Cycles of BV given Median 4 (range 1-9) 
Received stem-cell transplantation following BV  
Yes  
Autologous SCT 
Allogenic SCT 
No 
 
61 (61%) 
23 (23%) 
38 (38%) 
38 (38%) 
Abbreviations: BV; brentuximab vedotin, ORR; overall response rate, P(M)R; Partial (metabolic) response, 
C(M)R/CRu; complete (metabolic) response / unconfirmed complete response, SD; stable disease, PD; 
progressive disease, SCT; stem cell transplantation 
 
The key baseline characteristics of the 99 patients are outlined in Table II. The median age of the cohort 
treated with BV monotherapy was 32 years (range 13-70 years) with an equal gender distribution (male 45%; 
female 55%). The majority of patients within the cohort had nodular sclerosis histological subtype (n = 75; 
84%) and presented with an ECOG performance status of 0-1 in 94% of cases. Most patients presented with 
advanced stage disease (n = 69; (71%)) with bulky disease > 10 cm present in 21% of patients.  
Table III: Treatments received pre and post BV and response rates 
Treatment lines and response rates BV SCT-naive patients (n = 99) 
First line therapy (n = 99) 
ABVD alone 
ABVD to eBEACOPP/BEACOPP 
CHLVPP / ABVD 
ABVD to AVD 
OEPA/COPDAC 
Other  
RT as part of first line treatment 
 
73 (74%) 
7 (7%) 
3 (3%) 
4 (4%) 
7 (7%) 
5 (5%) 
7 
Response to first line chemotherapy 
ORR 
CR total (CMR / CR / Cru) 
PR total (PMR / PR) 
SD  
PD 
 
75 (76%) 
44 (44%) (25 (25%) / 16 (16%) / 3 (3%)) 
31 (31%) (10 (10%) / 21 (21%)) 
5 (5%) 
19 (19%) 
Second line therapy (n = 99) 
ESHAP 
DHAP 
IGEV 
ICE 
IVE 
BEACOPP/eBEACOPP 
ChVLLP based 
RT 
Other 
RT adjunct 
 
42 (42%) 
24 (24%) 
8 (8%) 
7 (7%) 
4 (4%) 
4 (4%) 
4 (4%) 
3 (3%) 
3 (3%) 
3 
Response to second line chemotherapy (n = 98) 
ORR 
CMR / CR 
PMR / PR 
SD  
PD 
 
47 (48%) 
4 (4%) / 6 (6%)  
4 (4%)/ 33 (34%) 
15 (15%) 
36 (37%) 
3rd line therapy if not BV ( n= 28) 
Mini-LEAM / Mini-BEAM 
GEM-P 
DHAP 
IGEV 
IVE 
ESHAP 
RT 
 
9 (32%) / 1 (4%) 
7 (25%) 
4 (14%) 
3 (11%) 
2 (7%) 
1 (4%) 
1 (4%) 
Response to non-BV third line chemotherapy (n = 28) 
ORR 
CMR / CR 
PMR / PR 
 
11 (39%) 
1 (4%) / 2 (7%)  
2 (7%)/ 6 (21%) 
SD  
PD 
4 (14%) 
13 (46%) 
Treatment post BV pre SCT 
 
Cohort failing to reach SCT 
 
Bendamustine 
Gemcitabine-based 
Mini-BEAM 
DECC 
RT 
Others 
 
Cohort successfully reaching SCT 
 
Bendamustine 
Gemcitabine-based 
Mini-BEAM/mini-LEAM 
RT 
Others 
 
 
 
 
11 
6 
6 
3 
5 
14 
 
 
 
7 
3 
12 
4 
5 
 
Response to BV according to subsequent 
transplantation 
Autologous SCT (n = 23) 
CMR/CR 
PMR/PR 
SD 
PD 
N/A 
ORR 
Allogenic SCT (n = 38) 
CMR/CR 
PMR/PR 
SD 
PD 
N/A 
ORR 
 
 
 
10 
7 
2 
3 
1 
77% 
 
16 
9 
3 
10 
0 
69% 
Abbreviations: ABVD; adriamycin, bleomycin, vinblastine, dacarbazine, (e)BEACOPP; (escalated) bleomycin, 
etoposide, adriamycin, cyclophosphamide, vincristine, prednisolone, procarbazine; CHLVPP; chlorambucil, 
vinblastine, prednisolone, procarbazine; OEPA/COPDAC; Vincristine, etoposide, prednisone, doxorubicin, 
cyclophosphamide, vincristine, prednisone, and dacarbazine; B(L)EAM; carmustine (lomustine), etoposide, 
cytarabine, melphalan; DECC; lomustine, etoposide, chlorambucil, dexamethasone;  BV; brentuximab vedotin, 
ICE; ifosfamide, carboplatin, etoposide, GEM-P; gemcitabine, methylprednisolone, cisplatin, DHAP; 
dexamethasone, high dose cytarabine, cisplatin; ESHAP; etoposide, high dose cytarabine, methylprednisolone, 
cisplatin, IVE; ifosfamide, epirubicin, etoposide, IGEV; ifosfamide, gemcitabine, vinorelbine RT; radiotherapy, 
ORR; overall response rate P(M)R; Partial (metabolic) response, C(M)R/CRu; complete (metabolic) response / 
unconfirmed complete response, SD; stable disease, PD; progressive disease,  
 
Table III displays the treatment patients received in our cohort both prior to and following BV monotherapy. 
The vast majority (74%) received ABVD induction regimen, either 2-4 cycles with involved field radiotherapy in 
early stage disease or 6 cycles (with bleomycin dropped in some more recently treated, iPET negative patients 
(4%)). Seven patients (7%) escalated intensity following a positive iPET to escalated BEACOPP or BEACOPP-14. 
The ORR to first line therapy was 76% (CR/CRu/CMR rate 41%; PR/PMR rate 25%) and the median length of the 
first remission in all measurable patients was 6 months (range 0.7 – 74 months). Second line therapy was most 
commonly ESHAP (42%) (etoposide, high dose cytarabine, methylprednisolone, cisplatin) or DHAP (24%) 
(dexamethasone, high dose cytarabine, cisplatin). IGEV (Ifosfamide, gemcitabine, vinorelbine) and ICE 
(ifosfamide, carboplatin, etoposide), and IVE (ifosfamide, epirubicin, etoposide) were all also regularly used 
second line regimens. Mini-BEAM / mini-LEAM (carmustine (lomustine), etoposide, cytarabine, melphalan) and 
GEM-P (gemcitabine, cisplatin, methylprednisolone) were often used third line. Response rates incrementally 
decreased with subsequent lines of therapy pre-BV (second line; ORR 48%; CR/CMR 10%; PR/PMR 38% and 
third line; ORR 39%; CR/CMR 11%’ PR/PMR 28%).  
Figure 1: treatment following BV 
 
 Response to BV monotherapy 
The overall median follow up from the start of BV was 12.0 months (range 0.4 - 56.7 months). The median time 
from prior therapy to starting BV was only 2.53 months (range 0.72 – 34.8 months). The best radiological ORR 
recorded as assessed by the local treating physician was 56% (complete metabolic response/complete 
response/complete response unconfirmed (CMR/CR/CRu) 29% plus partial metabolic response/partial 
8%
15%
19%
8%
19%
31%
BV then no further treatment
BV then ASCT
BV then alloSCT
BV then further treatment then
ASCT
BV then further treatment then
alloSCT
BV then further treatment only
response (PMR/PR) 27%) in the 96 patients assessable for response. Three patients developed toxicities and 
were never radiologically assessed. The median number of cycles of BV monotherapy received was 4 (range 1-
9). Sixty one percent (n = 61) received consolidation with either an allogenic (n = 38; 38%) or autologous SCT (n 
= 23; 23%). However, only 32% (n = 32) proceeded to SCT without requiring further treatment with 29% (n = 
29) requiring further treatment prior to receiving SCT (Figure 1). For those who proceed to ASCT (n = 14) 
immediately following BV, 64% were in CR and 36% were in PR. For those who proceeded to alloSCT 
immediately following BV (n = 18) the corresponding rates to BV were CR/CMR 67%, PR 22% and SD 11%. 
Post BV therapy 
Post BV therapy was variable, with the most commonly used options including bendamustine, gemcitabine, 
and radiotherapy. Of the 23 patients receiving an autologous SCT, 3 patients had progressive disease (PD) pre-
SCT and received bendamustine (n = 2) and mini-BEAM followed by GEM-P (n = 1). Of the 38 receiving 
allogenic SCT, 10 patients had PD pre-SCT and were salvaged by mini-BEAM/LEAM (n = 6), bendamustine (n = 
1), GEM-P (n = 1), R-IVE (n = 1) and radiotherapy (n = 1).  
 
Figure 2: Survival of patients following BV monotherapy  
Figure 2 panel (A-E) provides the key survival outcomes. The median PFS for all patients was 5.65 months (95% 
confidence interval (CI) 4.41 -  12.20 months) (panel A) and the median OS for all patients was 37.15 months 
(95% CI 18.28 months - not reached (NR)) (panel B). Patients who were consolidated with either an autologous 
or allogenic SCT had a superior PFS (panel C) and OS (panel D) (p < 0.001 for autologous and allogenic SCT 
when compared to non-SCT group for PFS and OS) to those patients that did not receive a consolidative SCT. 
The median OS and PFS of those groups were as follows: no SCT (median PFS 3.02 months (95% CI 2.50 -  4.41); 
median OS 12.19 months (95% CI 8.09 - 18.28 months)) vs autologous SCT (median PFS NR (95% CI 17.03 
months - NR); median OS NR (95% CI 27.02 months - NR)) vs allogenic SCT (median PFS NR (95% CI 5.59 
months - NR); median OS NR (95% CI 37.15 months - NR)). Patients with an improved initial remission to BV 
translated that response into an improved PFS (Panel E).  
Table IV summarises the findings of the univariate and multivariate analysis. Univariate predictors of PFS 
following BV treatment were baseline performance status at diagnosis ECOG 0 vs. 1 (Hazard ratio (HR) 2.19 
(95% CI 1.23 - 3.92; p = 0.008), baseline ECOG 0 vs. 2 (HR 3.93 (95% CI 1.32 - 11.65; p = 0.014)), haemoglobin at 
first relapse (continuous variable HR 0.77 (95% CI 0.65 - 0.92; p = 0.004)) and extranodal disease at first relapse 
(HR 1.86 (95% CI 1.11 - 3.14; p = 0.020)).  ECOG 0 vs. 1 at baseline and haemoglobin at first relapse factors 
remained statistically significant following multivariate analysis.  
Table IV: Univariate and multivariate predictors of progression or death 
A: Univariate predictors of progression or death 
Predictor Hazard ratio (95% CI) p 
Male gender 1.00 (0.60 - 1.67) 0.995 
ECOG 0 vs 1 at diagnosis 2.19 (1.23 - 3.92) 0.008 
ECOG 0 vs 2 at diagnosis 3.93 (1.32 - 11.65) 0.014 
Age (continuous)  1.01 (1.00 – 1.03) 0.152 
Stage I vs II at diagnosis 0.73 (0.10 - 5.57) 0.766 
Stage I vs III at diagnosis 0.82 (0.10 - 6.44) 0.852 
Stage I vs IV at diagnosis 1.20 (0.16 - 8.79) 0.860 
Bulk > 10 cm at diagnosis 0.85 (0.44 - 1.64) 0.621 
NS vs MC 1.35 (0.63 - 2.88) 0.434 
NS vs other 1.92 (0.59 - 6.21) 0.277 
First remission (continuous) 1.00 (0.99 - 1.02) 0.652 
Hb at first relapse (continuous) 0.77 (0.65 - 0.92) 0.004   
Extranodal disease at first relapse Y 1.86 (1.11 - 3.14) 0.020 
B symptoms at first relapse Y 1.61 (0.94 - 2.75) 0.084 
Stage II at first relapse 2.32 (0.31 - 17.71) 0.415 
Stage III at first relapse 2.36 (0.31 - 18.17) 0.409 
Stage IV at first relapse 3.38 (0.46 - 24.79) 0.232 
Prior lines of therapy 3 1.15 (0.64 - 2.05) 0.643 
Prior lines of therapy 4 1.61 (0.57 - 4.49) 0.367   
Time from last treatment to BV (continuous) 0.97 (0.92 - 1.03) 0.384 
Total Duration of HL time frame (continuous) 1.00 (0.99 - 1.01) 0.892 
B: Multivariate predictors of progression or death 
Characteristic Hazard ratio (95% CI) p 
Male gender 2.04 (1.05 - 3.96) 0.035 
ECOG 0 vs 1 at diagnosis 2.19 (1.18 -  4.04) 0.013 
ECOG 0 vs 2 at diagnosis 2.40 (0.76 - 7.54) 0.136 
Hb at first relapse (continuous) 0.66 (0.54 - 0.80) 0.000 
Table V describes the AEs reported by local physicians during BV monotherapy. Causality and CTCAE v 4.03 
grading was formally assessed where possible given the retrospective nature of this study. BV was generally 
well tolerated, with no AEs reported in 63 (64%) of the 99 patients. The commonest reported AEs were 
neutropenia (grade 1-2 n =9; grade 3-4 n = 6; not known n = 2), anaemia (n = 7; all grade 1), non-neutropenic 
infection (grade 1-2 n = 5; grade 3-4 n = 4; grade 5 n = 1) and sensory peripheral neuropathy (grade 1-2 n = 7; 
grade 3-4 n = 2).  There were no previously undescribed AEs thought related to BV.  
Table V: Adverse Events – possible, probably or definitely related to brentuximab vedotin 
Adverse Events reported (n = 99) Total number of events 
 
Patients experiencing no related toxicity 63 
Neutropenic Fever 0 
Non neutropenic Infection 
G2 
G3 
G5 
 
5 
4 
1 
Haematological 
Neutropenia 
G1 
G2 
G3 
G4 
NK 
Anaemia 
G1 
Thrombocytopenia 
G1 
 
 
4 
5 
4 
2 
2 
 
7 
 
1 
Allergic Reaction 
G2 
G3 
 
2 
1 
Gastroenterological 
Mucositis 
G1 
Vomiting 
G1 
Nausea 
                                                  G1 
Constipation 
G2 
 
 
1 
 
1 
 
1 
 
1 
Peripheral Neuropathy 
G1 
G2 
G3 
 
4 
3 
2 
Rash 
G1 
G3 
 
1 
1 
Flu-like Symptoms 
G1 
Fatigue 
G1 
Myalgia 
G1 
 
3 
 
2 
 
4 
Others 3 
 
Discussion 
Despite the unavoidable limitations of a retrospective non-randomized study, this is the largest series to date 
outlining the efficacy and survival of patients with relapsed / refractory cHL treated with BV monotherapy 
prior to planned SCT. Our series (n = 99) provides extensive coverage across the United Kingdom, with data 
provided from major tertiary referral units and provides an accurate representation of the patient population 
in need of novel therapies in this area. The ORR of 56% (complete metabolic response/complete 
response/complete response unconfirmed (CMR/CR/CRu) 29% plus partial metabolic response/partial 
response (PMR/PR) 27%) highlights the efficacy of BV in this difficult-to-treat, chemotherapy-refractory 
population. Response rates recorded in our cohort are consistent with that reported within the summarised 
literature in Table 1. The overall PFS for all patients of 5.65 months (95% CI 4.41 - 12.20 months) is however 
modest. This is reflected in the fact that over half of patient who were consolidated with a SCT required at 
least 1 further line of therapy post-BV before consolidation SCT. Patients who initially only responded partially 
had a short median PFS of 6.48 months (95% 4.73 – NR) and therefore required consolidation therapy in 
remission as responses were non-durable. Patients with a complete response had more durable remissions 
with the median duration of remission not reached.  
It is very difficult to conclude from this data as to which form of SCT consolidation is superior. The ORR to BV in 
those receiving autologous SCT may have had some influence over the seemingly improved PFS curve when 
compared to those receiving allogenic SCT. There was no OS difference between the two strategies and type of 
SCT was very dependent of physician and centre preference within the cohort as a whole rather than direct 
patient characteristics per se. Our study was not designed to answer the question of whether alternative 
treatment options are superior to BV or which consolidation SCT strategy is best. Overall, BV was very well 
tolerated in this setting and highlights the value of relatively non-toxic regimens in the preparation for more 
toxic SCT subsequent therapy.  
Univariate and multivariate analysis were performed to provide potential predictors of outcome in patients 
treated with BV monotherapy. Patients with a superior ECOG performance status had an overall superior 
outcome. However as this was not a randomised trial we cannot state which patients would definitely derive 
most benefit from BV.  
The potential weaknesses of our retrospective study include the lack of centralised pathology review of 
biopsies from diagnosis or relapse, the lack of formalised radiological reporting according to published criteria 
(Barrington et al., 2014; Cheson et al., 2014) and the lack of prospective reporting of AEs and documentation 
of causality.  
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